Edition:
India

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

7.30USD
19 Jan 2018
Change (% chg)

$0.10 (+1.39%)
Prev Close
$7.20
Open
$7.30
Day's High
$7.40
Day's Low
$7.30
Volume
7,429
Avg. Vol
19,736
52-wk High
$11.73
52-wk Low
$5.60

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $123.10
Shares Outstanding(Mil.): 16.86
Dividend: --
Yield (%): --

Financials

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

19 Oct 2017

BRIEF-Cidara Q2 net loss per share $0.99​

* Cidara provides corporate update and reports second quarter 2017 financial results

10 Aug 2017

BRIEF-Cidara Therapeutics updates on results from studies investigating antifungal CD101

* Cidara therapeutics inc - ‍announces publication of results from in vivo study investigating novel antifungal CD101 in intra-abdominal candidiasis (IAC)​

01 Aug 2017

Earnings vs. Estimates